Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.75 |
| ▸ | GAA | P10253 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31546426 | 0.86 | MAPT (0.78) | MAPTGAANPC1LMNAHTT | |
| SCHEMBL28667773 | 0.83 | MAPT (0.62) | MAPTGAANPC1SMN1; SMN2LMNA | |
| SCHEMBL31546357 | 0.83 | MAPT (0.63) | MAPTGAANPC1SMN1; SMN2LMNA | |
| SCHEMBL30584791 | 0.82 | MAPT (0.63) | MAPTNPC1RAB9ALMNAHTT | |
| SCHEMBL30584898 | 0.81 | MAPT (0.64) | MAPTGAANPC1SMN1; SMN2LMNA | |
| SCHEMBL28930626 | 0.81 | MAPT (0.68) | MAPTGAASMN1; SMN2RAB9ALMNA | |
| SCHEMBL25403067 | 0.80 | MAPT (0.61) | MAPTNPC1SMN1; SMN2LMNAHTT | |
| SCHEMBL29165624 | 0.79 | MAPT (0.63) | MAPTNPC1SMN1; SMN2LMNAHTT | |
| SCHEMBL28432321 | 0.78 | MAPT (0.64) | MAPTGAASMN1; SMN2RAB9ALMNA | |
| SCHEMBL31546316 | 0.78 | MAPT (0.76) | MAPTNPC1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | MAPT 2999/4885GAA 3585/4885NPC1 2341/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | MAPT 2999/4885GAA 3585/4885NPC1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.